Precipio's 2025 10-K Reveals 30% Revenue Jump to $24M, Net Loss Narrows Sharply
Summary
Precipio, Inc. announced its fiscal year 2025 results via its 10-K filing, reporting net sales of $24.0 million, a 30% increase from the prior year, and a basic and diluted loss per common share of $(0.23). The company notably narrowed its net loss to $(0.363) million, a significant improvement from $(4.290) million in 2024, driven by higher case volumes and expanded gross margins of 45%. These results demonstrate strong operational progress and revenue growth, suggesting improved financial health and scalability for the diagnostics firm. Traders will be watching for continued momentum in revenue growth and further progress towards profitability as the company leverages its lab capacity and product commercialization efforts.
At the time of this announcement, PRPO was trading at $23.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.9M. The 52-week trading range was $3.90 to $29.53. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.